Cerity Partners LLC Buys 24,241 Shares of Johnson & Johnson $JNJ

Cerity Partners LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,806,885 shares of the company’s stock after acquiring an additional 24,241 shares during the quarter. Cerity Partners LLC’s holdings in Johnson & Johnson were worth $373,990,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Omnitrust Wealth Management Inc bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $217,000. LeClair Wealth Partners LLC boosted its stake in Johnson & Johnson by 14.4% during the 4th quarter. LeClair Wealth Partners LLC now owns 1,263 shares of the company’s stock valued at $261,000 after purchasing an additional 159 shares during the period. LPL Financial LLC boosted its stake in Johnson & Johnson by 1.1% during the 4th quarter. LPL Financial LLC now owns 5,042,090 shares of the company’s stock valued at $1,043,461,000 after purchasing an additional 54,322 shares during the period. Erste Asset Management GmbH boosted its stake in Johnson & Johnson by 10.4% during the 4th quarter. Erste Asset Management GmbH now owns 368,399 shares of the company’s stock valued at $76,415,000 after purchasing an additional 34,711 shares during the period. Finally, Manchester Capital Management LLC boosted its stake in Johnson & Johnson by 3.8% during the 4th quarter. Manchester Capital Management LLC now owns 22,386 shares of the company’s stock valued at $4,633,000 after purchasing an additional 820 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $232.17 on Tuesday. The stock has a 50 day moving average of $231.83 and a two-hundred day moving average of $226.38. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a market capitalization of $558.89 billion, a P/E ratio of 26.84, a P/E/G ratio of 2.28 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the prior year, the firm posted $2.77 EPS. Johnson & Johnson’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is currently 61.97%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson agreed to buy Firefly Bio for $1 billion, adding a novel degrader antibody conjugate platform that could broaden its oncology pipeline and improve its position in difficult-to-treat cancers. Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
• Positive Sentiment: The Firefly deal signals continued capital deployment into high-value cancer assets, which can support investor confidence in J&J’s long-term earnings growth beyond its core healthcare franchise. Johnson & Johnson to buy Firefly Bio for $1 billion
• Neutral Sentiment: Commentary highlighting J&J as a “cheap robotics stock” focused on coronary artery disease treatment may reinforce the company’s medical technology story, but it is not a major new catalyst on its own. Johnson & Johnson (JNJ): A Cheap Robotics Stock Redefining Coronary Artery Disease Treatment
• Neutral Sentiment: A separate mention that J&J received a buy rating from Guggenheim may be supportive, but the note appears older and less likely to be driving today’s move. Johnson & Johnson (JNJ) Gets a Buy from Guggenheim

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Wells Fargo & Company increased their target price on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 15th. Finally, Daiwa Securities Group raised their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research report on Thursday, April 16th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.